In creating a new clinical data network, PACeR endeavors to:
- support improvement in patient care and the research missions of participating institutions;
- improve the operational efficiency and scientific integrity of clinical research;
- advance the objectives of medical institutions regarding the primary and secondary use of clinical data; and
- serve as a viable, practical model for other states, regions, and the nation, that recommends solutions to relevant technical, legal, regulatory, economic, and operational issues.
Key highlights in PACeR's development:
Phase 1 of PACeR identified barriers to the secondary use of electronic health data for evidence-based research, and developed recommendations to address those barriers.
Phase 2 is working to demonstrate the practical feasibility of the secondary use of electronic clinical data through projects in 2012-2014. Specific Phase 2 goals include:
- establishing a PACeR clinical data nomenclature standardization entity;
- forming a PACeR “market making” capability to streamline and deliver protocol modeling and patient selection services using data from multiple institutions;
- exploring the feasibility of establishing a PACeR Privacy Board to create an improved approach for the use of de-identified clinical data for trial modeling;
- developing and implementing software solutions that “wrap around” currently used EMR systems;
- to capture additional data, using standardized clinical nomenclature;
- creating technology, methods, policies, and procedures that will allow patients to determine when and how their data are used for research; and
- developing a statewide PACeR patient education program.
Phase 2 continues to be led by a broadly representative leadership committee. PACeR strongly encourages additional participants in Phase 2. We welcome the perspectives of new members such as physician professional societies, community hospitals, device manufacturers, EMR vendors, disease societies, and others. The more comprehensive PACeR's membership, the more sustainable its approach becomes.
Several projects are currently underway with major Pharma companies in areas of patient identification through data capture tools and mining strategies. Additional projects are under consideration and may include capabilities such as remote monitoring and SDV reduction via single-source data entry, as well as medical device safety surveillance and uniform identification number tracking.